Business
Nicox Extends Existing Flexible Equity Financing
Press Release Nicox Extends Existing Flexible Equity Financing 5 million shares added to the existing equity financing line with Vester Finance NCX 470 Denali confirmatory Phase 3 results expected mid-August to mid-September 2025 August 08, 2025 – release at 7:30 am Sophia Antipolis, FranceNicox SA (Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology company, today announced an extension of the PACEO1 equity line of financing entered into with Vester Finance on March 5, 2
About this update from Nicox Sa
1 Programme d’Augmentation de Capital par Exercice d’Options (Capital increase program through exercise of warrants) 2 Non-diluted share capital as of 31 July 2025 3 Taking into account the issue of 39,536,771 new shares issuable at the date of this press release on the exercise of stock options (1,187,205 shares), the vesting of restricted stock (4,072,785 shares), the exercise of warrants (20,234,228 shares) and the conversion of bonds convertible into equity (14,042,553 shares) 4 The lowest volume-weighted average daily price of the share over the two consecutive trading sessions preceding an exercise request, after applying a maximum discount of 6.5% 5 Closing price of €0.62 on August 7, 2025 6 Delegation of competence to the Board of Directors to increase the share capital for the benefit of a category of investors without preferential right of subscription of the shareholders Attachment